dr. drilon on the safety profile of brigatinib in alk nsclc
Published 4 years ago • 149 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
1:52
dr. drilon on the utility of brigatinib in alk nsclc
-
1:11
dr. rotow on brigatinib safety profile in alk nsclc
-
1:05
dr. drilon on immunotherapy in lung cancer
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
1:34
dr. pennell on the use of brigatinib in alk nsclc
-
2:12
dr. drilon on entrectinib in patients with ros1-positive nsclc
-
1:39
dr. leach on brigatinib in alk-positive nsclc
-
0:50
dr. drilon on comprehensive sequencing in lung cancer
-
2:05
alta-1l: brigatinib vs crizotinib in nsclc
-
3:05
dr. drilon discusses the results of the phase i/ii libretto-001 trial
-
2:13
alk nsclc: brigatinib indication and alta trial
-
4:37
fda approval of brigatinib for alk nsclc
-
1:36
dr. drilon on targeted therapies for patients with ros1-rearranged lung cancer
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
6:51
progression in alk nsclc after frontline therapy
-
1:12
dr. drilon on ret rearrangements in nsclc
-
8:16
alta ii trial of brigatinib in alk-rearranged nsclc
-
5:19
brigatinib at disease progression of alk-rearranged nsclc
-
0:52
dr. rotow on remaining questions with brigatinib in alk nsclc